Work

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8047

Authors: Scott N. Gettinger, Lyudmila Bazhenova, Ravi Salgia, Corey J. Langer, Kathryn A. Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss, Narayana I. Narasimhan, David J. Dorer, Victor M. Rivera, Tim Clackson, Frank G. Haluska, D. Ross Camidge

Institutions: Yale University, Moores Cancer Center, University of Chicago, Abramson Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Institut Català d'Oncologia, Massachusetts General Hospital, Cancer Treatment Centers of America, ARIAD Pharmaceuticals (United States), University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603848258

Cites:

Cited by: 40

Related to: 10